PURPOSE: The epidemiology, classification, pathology, and treatment of diabetic neuropathy are reviewed. SUMMARY: Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant morbidity and mortality. Some 30% of hospitalized and 20% of community-dwelling diabetes patients have peripheral neuropathy; the annual incidence rate is approximately 2%. The primary risk factor is hyperglycemia. Sensorimotor neuropathy is marked by pain, paresthesia, and sensory loss. Cardiac autonomic neuropathy (CAN) may contribute to myocardial infarction, malignant arrhythmia, and sudden death. Gastroparesis is the most debilitating complication of gastrointestinal autonomic neuropathy. Genitourinary autonomic neuropathy can cause sexual dysfunction and neurogenic bladder. The pathology of diabetic neuropathy involves oxidative stress, advanced glycation end products, polyol pathway flux, and protein kinase C activation; all contribute to microvascular disease and nerve dysfunction. For symptom management current evidence from clinical trials supports the use of desipramine, amitriptyline, capsaicin, tramadol, gabapentin, bupropion, and venlafaxine as preferred medications. Citalopram, nonsteroidal antiinflammatory drugs, and opioid analgesics may be used as adjuvant agents. Lamotrigine, oxcarbazepine, paroxetine, levodopa, and alpha-lipoic acid are alternative considerations. Evidence supporting the use of zonisamide, fluoxetine, mexiletine, dextromethorphan, and phenytoin is considered equivocal. Complementary therapies have also shown efficacy. The symptoms of CAN may be ameliorated with fludrocortisone, clonidine, midodrine, dihydroergotamine or caffeine, octreotide, and beta-blockers. Gastroparesis may be treated with metoclopramide or erythromycin. The most promising disease-modifying therapy is ruboxistaurin, which is in Phase III trials. Glycemic control remains the foundation of prevention and the prerequisite of adequate treatment. CONCLUSION: Diabetic neuropathy is a many-faceted complication of diabetes that can be managed symptomatically with an array of drugs.

 

This article has been cited by other articles:

				A M Drewes, A L Krarup, S Detlefsen, M-L Malmstrom, G Dimcevski, and P Funch-Jensen Pain in chronic pancreatitis: the role of neuropathic pain mechanisms Gut, November 1, 2008; 57(11): 1616 - 1627. [Abstract] [Full Text] [PDF]

				J. D Evans, T. F Jacobs, and E. W Evans Role of Acetyl-L-Carnitine in the Treatment of Diabetic Peripheral Neuropathy Ann. Pharmacother., November 1, 2008; 42(11): 1686 - 1691. [Abstract] [Full Text] [PDF]

				K. A. Muller, J. M. Ryals, E. L. Feldman, and D. E. Wright Abnormal Muscle Spindle Innervation and Large-Fiber Neuropathy in Diabetic Mice Diabetes, June 1, 2008; 57(6): 1693 - 1701. [Abstract] [Full Text] [PDF]

				G.-Q. Song and J. D. Z. Chen Synchronized gastric electrical stimulation improves delayed gastric emptying in nonobese mice with diabetic gastroparesis J Appl Physiol, November 1, 2007; 103(5): 1560 - 1564. [Abstract] [Full Text] [PDF]

				R. G. Smith Painful Diabetic Peripheral Neuropathy J Am Podiatr Med Assoc, September 1, 2007; 97(5): 394 - 401. [Abstract] [Full Text] [PDF]

				N. Papanas and E. Maltezos Growth Factors in the Treatment of Diabetic Foot Ulcers: New Technologies, Any Promises? International Journal of Lower Extremity Wounds, March 1, 2007; 6(1): 37 - 53. [Abstract] [PDF]

				M. M. Huizinga and A. Peltier Painful Diabetic Neuropathy: A Management-Centered Review Clin. Diabetes, January 1, 2007; 25(1): 6 - 15. [Abstract] [Full Text] [PDF]

				T. S. Foster Efficacy and Safety of {alpha}-Lipoic Acid Supplementation in the Treatment of Symptomatic Diabetic Neuropathy The Diabetes Educator, January 1, 2007; 33(1): 111 - 117. [Abstract] [Full Text] [PDF]

				C. J. Diskin, T. J. Stokes, L. M. Dansby, L. Radcliff, and T. B. Carter Massive increase in proteinuria after the introduction of midodrine in an elderly patient--a case report Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1988 - 1988. [Full Text] [PDF]

				C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean Consensus Guidelines: Treatment Planning and Options Mayo Clin. Proc., April 1, 2006; 81(4_Suppl): S12 - S25. [Abstract] [Full Text] [PDF]

				J. Asbun and F. J. Villarreal The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy J. Am. Coll. Cardiol., February 21, 2006; 47(4): 693 - 700. [Abstract] [Full Text] [PDF]

				A. Salonia, R. Lanzi, M. Scavini, M. Pontillo, E. Gatti, G. Petrella, G. Licata, R. E. Nappi, E. Bosi, A. Briganti, et al. Sexual Function and Endocrine Profile in Fertile Women With Type 1 Diabetes Diabetes Care, February 1, 2006; 29(2): 312 - 316. [Abstract] [Full Text] [PDF]